<code id='D7333DAFFC'></code><style id='D7333DAFFC'></style>
    • <acronym id='D7333DAFFC'></acronym>
      <center id='D7333DAFFC'><center id='D7333DAFFC'><tfoot id='D7333DAFFC'></tfoot></center><abbr id='D7333DAFFC'><dir id='D7333DAFFC'><tfoot id='D7333DAFFC'></tfoot><noframes id='D7333DAFFC'>

    • <optgroup id='D7333DAFFC'><strike id='D7333DAFFC'><sup id='D7333DAFFC'></sup></strike><code id='D7333DAFFC'></code></optgroup>
        1. <b id='D7333DAFFC'><label id='D7333DAFFC'><select id='D7333DAFFC'><dt id='D7333DAFFC'><span id='D7333DAFFC'></span></dt></select></label></b><u id='D7333DAFFC'></u>
          <i id='D7333DAFFC'><strike id='D7333DAFFC'><tt id='D7333DAFFC'><pre id='D7333DAFFC'></pre></tt></strike></i>

          entertainment

          entertainment

          author:fashion    Page View:19672
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Medicare Advantage 2025 payments will dip, Biden administration says
          Medicare Advantage 2025 payments will dip, Biden administration says

          AdobeOverthepastfewweeks,MedicareAdvantageinsurersdemandedthattheBidenadministrationgivethemhigherpa

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          AstraZeneca lung cancer study comes in below expectations

          LONDON—AstraZenecasaidonMondaythatanewlungcancertreatmentoutperformedstandard-of-carechemotherapyina